Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
– Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic use
– Agreement valued at approximately $135 million
GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby Emergent will deploy its contract development and manufacturing (CDMO) services to support the manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19 that leverages the AdVac® and PER.C6® technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson.
Click below to listen to our board member, Gene McWilliams, participating in Neumann University’s Coronacast. Subscribe to Neumann’s YouTube channel for over 75 Coronacasts from all over the world.
Click below to watch a coverage of Neumann’s Coronacast on Fox 29